Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma

Abstract

Introduction and Objectives: Lenalidomide is considered a standard of care in multiple myeloma (MM) Some MM patients will develop delayed hypersensitivity to lenalidomide, which can lead to treatment discontinuation. Desensitization to lenalidomide can help these patients to complete treatment courses. Here, we aimed to review lenalidomide-treated MM patients who developed delayed hypersensitivity-induced rash and were treated with desensitization.Methods: A retrospective analysis of medical files of MM patients, who were desensitized to lenalidomide due to delayed hypersensitivity rash. Patients were treated between 2018 and 2022 at

A Tailored 7- to 10-Day Lenalidomide Desensitization Protocol

“…Few data have been published on desensitization with lenalidomide. Previously proposed protocols are long (lasting between 16 days and 7 months), complicated, and, sometimes, clinically inapplicable [7][8][9]. Our group previously reported a case of desensitization to lenalidomide based on a shorter and more effective protocol [1].…”

“…Very little experience and few protocols have been reported for desensitization to lenalidomide [7][8][9]11]. One case series in Japan reported 5 patients who successfully completed their desensitization protocol.…”